Ashvin Patel, MD
Psychiatry · Richmond, VANPI 1730209172
Payments from drug & device makers
Across 953 payments — averaging $71.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$49K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$6K
- Johnson & Johnson$2K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Corium, LLC$967
- plus $8K from 25 others
What the payments were for
- Speaking & faculty fees$50,10574%
- Travel & lodging$6321%
- Food & beverage$17,04425%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 259 | $48,949 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 112 | $6,028 |
| Johnson & Johnson | 64 | $1,811 |
| Alkermes, Inc. | 53 | $1,318 |
| Otsuka America Pharmaceutical, Inc. | 49 | $1,209 |
| Corium, LLC | 40 | $967 |
| Neurocrine Biosciences, Inc. | 39 | $877 |
| Lundbeck LLC | 45 | $839 |
| Vanda Pharmaceuticals Inc. | 28 | $775 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $753 |
| Supernus Pharmaceuticals, Inc. | 15 | $574 |
| Sunovion Pharmaceuticals Inc. | 24 | $562 |
| Ironshore Pharmaceuticals Inc. | 28 | $496 |
| Axsome Therapeutics, Inc. | 12 | $399 |
| Bausch Health US, LLC | 19 | $385 |
| E.r. Squibb & Sons, L.L.C. | 14 | $315 |
| Neos Therapeutics, LP | 13 | $224 |
| Tris Pharma Inc | 18 | $218 |
| Avanir Pharmaceuticals, Inc. | 10 | $212 |
| Collegium Pharmaceutical, Inc. | 15 | $200 |
| Eisai Inc. | 10 | $152 |
| Teva Pharmaceuticals USA, Inc. | 8 | $123 |
| Jazz Pharmaceuticals Inc. | 7 | $113 |
| Neuronetics, Inc. | 4 | $95 |
| Merck | 5 | $75 |
| Noven Therapeutics, LLC | 5 | $71 |
| Idorsia Pharmaceuticals US Inc | 4 | $63 |
| Almatica Pharma LLC | 2 | $34 |
| Indivior Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$46,055
- CAPLYTA$4,294
- ARISTADA$434
- QELBREE$352
- SPRAVATO$252
- LATUDA$229
- REXULTI$125
- Fanapt$122
- Auvelity$119
- ABILIFY MAINTENA$117
- INVEGA SUSTENNA$115
- ARISTADA INITIO$109
- Azstarys$105
How this compares
$67,884 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $197,150 |
| VraylarCariprazine Hcl | 64 | $114,785 |
| AristadaAripiprazole Lauroxil | 12 | $35,595 |
| TrintellixVortioxetine Hydrobromide | 32 | $25,520 |
| RexultiBrexpiprazole | 16 | $23,019 |
| EmsamSelegiline | 11 | $22,105 |
| SpravatoEsketamine Hcl | 17 | $21,394 |
| BelsomraSuvorexant | 47 | $19,873 |
| Depakote ErDivalproex Sodium | 15 | $13,196 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $10,412 |
| Aripiprazole | 153 | $10,316 |
| Atomoxetine Hcl | 16 | $5,915 |
| Quetiapine Fumarate | 217 | $5,371 |
| Clomipramine Hcl | 17 | $4,649 |
| InvegaPaliperidone | 12 | $4,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $877 | $197,15024 claims |
| AbbVieVraylar | $48,949 | $114,78564 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $753 | $35,93354 claims |
| Alkermes, Inc.Aristada | $1,318 | $35,59512 claims |
| Johnson & JohnsonSpravato, Invega | $1,811 | $25,73429 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,209 | $23,01916 claims |
| MerckBelsomra | $75 | $19,87347 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Richmond
- Frederick MoellerRichmond$678K
- Susan KornsteinRichmond$87K
- Joel SteinbergRichmond$40K
- James SellmanRichmond$18K
- Robert SewardRichmond$14K
- William KernodleRichmond$14K
- John LeeRichmond$10K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.